DiscoverProject Oncology®Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Update: 2025-09-16
Share

Description

Host: Ryan Quigley




In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma